Evolocumab
20110118
Phase 3 mab completed
Quick answer
Evolocumab for Dyslipidemia is a Phase 3 program (mab) at Amgen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Dyslipidemia
- Phase
- Phase 3
- Modality
- mab
- Status
- completed